Xiaojun Chen
Clinical trials sponsored by Xiaojun Chen, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simpler lymph node check replace major surgery for endometrial cancer? Results expected Jan 2027 (estimated)
-
Can weight management plus hormones reverse precancerous uterine changes and preserve fertility?
Disease control Recruiting nowThis study is for overweight or obese women aged 18–45 with atypical endometrial hyperplasia, a precancerous condition of the uterine lining. Participants will receive either a levonorgestrel-releasing IUD (Mirena) or megestrol acetate pills, combined with a weight management pro…
Phase 2/3 • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in obese progestin-insensitive early-stage endometrial cancer patients with conservative treatment
Recruiting nowTo investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
Phase 2/3 • Sponsor: Xiaojun Chen
Last updated Sep 10, 2026 16:00 UTC
-
Gonadotropin-releasing hormone agonist (GnRHa) plus letrozole in non-obese progestin-insensitive early-stage endometrial cancer and atypical hyperplasia patients with conservative treatment
Recruiting nowTo investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.
Phase 2/3 • Sponsor: Xiaojun Chen
Last updated Sep 10, 2026 16:00 UTC